Non-CSCs or differentiated tumor cells demonstrated reduced sensitivity to NK cells, a phenomenon tied to their lower expression of NKp30 and NKp44 ligands for NCR NK cell-activating receptors compared to CSCs [29]. The gene discussed is NCR2; the disease is neoplasm.